Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers

Neurobiology of Disease

Volumn 37, Issue 2, 2010, Pages 356-361

  Pavese, Nicola ^a   Politis, Marios ^a   Tai, Yen F ^a   Barker, Roger A ^b   Tabrizi, Sarah J ^c   Mason, Sarah L ^b   Brooks, David J ^a   Piccini, Paola ^a  

^a MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cortex; Huntington's disease; PET; Raclopride

Indexed keywords

DOPAMINE 2 RECEPTOR; RACLOPRIDE C 11;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; FRONTAL CORTEX; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; IMAGE PROCESSING; INDIVIDUALITY; MALE; MENTAL FUNCTION; MOTOR DYSFUNCTION; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; SCORING SYSTEM; SYMPTOMATOLOGY; TEMPORAL CORTEX;

ADULT; BINDING, COMPETITIVE; CARBON RADIOISOTOPES; CEREBRAL CORTEX; DOPAMINE; DOPAMINE ANTAGONISTS; FEMALE; FRONTAL LOBE; GENETIC MARKERS; HETEROZYGOTE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RACLOPRIDE; RECEPTORS, DOPAMINE D2; TEMPORAL LOBE;

EID: 73049110382     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.10.015     Document Type: Article

References (19)

1. Brandt J., and Butters N. Neuropsychological characteristics of Huntington's disease. In: Grant I., and Adams K.M. (Eds). Neuropsychological Assessment of Neuropsychiatric Disorders (1996), Oxford University Press, New York 312-341
2. Friston K.J., Holmes A.P., Worsley K.J., Poline J.B., Frith C.D., and Frackowiak R.S. Statistical parametric maps in functional imaging: a general linear approach. Hum. Brain Mapp. 2 (1995) 189-210
3. Gunn R.N., Lammertsma A.A., Hume S.P., and Cunningham V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6 (1997) 279-287
4. Hedreen J.C., Peyser C.E., Folstein S.E., and Ross C.A. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci. Lett. 133 (1991) 257-261
5. Hennenlotter A., Schroeder U., Erhard P., Haslinger B., Stahl R., Weindl A., von Einsiedel H.G., Lange K.W., and Ceballos-Baumann A.O. Neural correlates associated with impaired disgust processing in pre-symptomatic Huntington's disease. Brain 127 (2004) 1446-1453
6. Ho A.K., Sahakian B.J., Brown R.G., Barker R.A., Hodges J.R., Ané M.N., Snowden J., Thompson J., Esmonde T., Gentry R., Moore J.W., Bodner T., and NEST-HD Consortium. Profile of cognitive progression in early Huntington's disease. Neurology 61 (2003) 1702-1706
7. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov. Disord. 11 (1996) 136-142
8. Lemiere J., Decruyenaere M., Evers-Kiebooms G., Vandenbussche E., and Dom R. Cognitive changes in patients with Huntington's disease (HD) and premanifest carriers of the HD mutation-a longitudinal follow-up study. J. Neurol. 251 (2004) 935-942
9. Quinn N., Brown R., Craufurd D., Goldman S., Hodges J., Kieburtz K., Lindvall O., MacMillan J., and Roos R. Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD). Mov. Disord. 11 (1996) 143-150
10. Paulsen J.S., Zimbelman J.L., Hinton S.C., Langbehn D.R., Leveroni C.L., Benjamin M.L., Reynolds N.C., and Rao S.M. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's disease. AJNR Am. J. Neuroradiol. 25 (2004) 1715-1720
11. Pavese N., Andrews T.C., Brooks D.J., Ho A.K., Rosser A.E., Barker R.A., Robbins T.W., Sahakian B.J., Dunnett S.B., and Piccini P. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 126 (2003) 1127-1135
12. Penney Jr. J.B., Vonsattel J.P., MacDonald M.E., Gusella J.F., and Myers R.H. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol. 41 (1997) 689-692
13. Reading S.A., Dziorny A.C., Peroutka L.A., Schreiber M., Gourley L.M., Yallapragada V., Rosenblatt A., Margolis R.L., Pekar J.J., Pearlson G.D., Aylward E., Brandt J., Bassett S.S., and Ross C.A. Functional brain changes in presymptomatic Huntington's disease. Ann. Neurol. 55 (2004) 879-883
14. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., Cudkowicz M.E., Caplan K., Marek K., Seidman L.J., Makris N., Jenkins B.G., and Goldstein J.M. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 60 (2003) 1615-1620
15. Spinks T.J., Jones T., Bailey D.L., Townsend D.W., Grootoonk S., Bloomfield P.M., Gilardi M.C., Casey M.E., Sipe B., and Reed J. Physical performance of a positron tomograph for brain imaging with retractable septa. Phys. Med. Biol. 37 (1992) 1637-1655
16. Spinks T.J., Jones T., Bloomfield P.M., Bailey D.L., Miller M., Hogg D., Jones W.F., Vaigneur K., Reed J., Young J., Newport D., Moyers C., Casey M.E., and Nutt R. Physical characteristics of the ECAT EXACT 3D positron tomograph. Phys. Med. Biol. 45 (2000) 2601-2618
17. Verny C., Allain P., Prudean A., Malinge M.C., Gohier B., Scherer C., Bonneau D., Dubas F., and Le Gall D. Cognitive changes in asymptomatic carriers of the Huntington disease mutation gene. Eur. J. Neurol. 14 (2007) 1344-1350
18. Wolf R.C., Vasic N., Schönfeldt-Lecuona C., Landwehrmeyer G.B., and Ecker D. Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. Brain 130 (2007) 2845-2857
19. Zimbelman J.L., Paulsen J.S., Mikos A., Reynolds N.C., Hoffmann R.G., and Rao S.M. fMRI detection of early neural dysfunction in preclinical Huntington's disease. J. Int. Neuropsychol. Soc. 13 (2007) 758-769